CXCR5 and T-cell non-Hodgkin lymphoma: We envision that CXCR5 CAR-T cell therapy may also be suitable for the treatment of CXCR5+ T-cell lymphoma entities because of the developmental relationship between Tfh cells and these T cell malignancies, both sharing CXCR5 as a potential target.